Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Eziefule O.M.; Arozal W.; Wanandi S.I.; Dewi S.; Nafrialdi; Saraswati M.; Louisa M.
Eziefule, Oluebube Magnificient (58945175000); Arozal, Wawaimuli (32067462200); Wanandi, Septelia Inawati (36099320700); Dewi, Syarifah (57192904541); Nafrialdi (57833636900); Saraswati, Meilania (57208472364); Louisa, Melva (41461551400)
58945175000; 32067462200; 36099320700; 57192904541; 57833636900; 57208472364; 41461551400
Andrographis paniculata: A potential supplementary therapy for cardiovascular diseases - A systematic review of its effects and molecular actions
2024
Journal of Pharmacy and Pharmacognosy Research
12
3
488
513
25
0
Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Kampus UI Salemba, Central Jakarta, 10430, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia
Eziefule O.M., Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Kampus UI Salemba, Central Jakarta, 10430, Indonesia; Arozal W., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Wanandi S.I., Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Dewi S., Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Nafrialdi, Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Saraswati M., Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia; Louisa M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, JI. Salemba, Raya No. 6, Jakarta, 10430, Indonesia
Context: Cardiovascular diseases claim the lives of an estimated 17.9 million people worldwide (report by the World Health Organization), yet the drug pipeline compared to some other life-threatening diseases, including cancer and neurological disorders, is low. Aims: To investigate the potential of Andrographis paniculata as a supplementary therapy for cardiovascular diseases based on recent in vivo animal studies. Methods: This study adopted a systematic review approach to analyze preclinical evidence from in vivo animal studies. Three databases (PubMed, Scopus, and Embase) were searched using the keywords "Andrographis paniculata", "cardiovascular disease", "CVD", "heart disease", "cardioprotective", "cardio*", "inflammation", "oxidative stress", "obesity", "lipopolysaccharide", "hypertension", "arrhythmia"and "aortic disease". The search period was from April 20th, 2023, to April 26th, 2023, and included studies published from 2013 to 2023. Only in vivo animal studies were appraised. In contrast, clinical studies, in vitro studies, in silico studies, and review papers were excluded. SYRCLE's risk of bias tool was used to assess the risk of bias. Results: Sixteen eligible in vivo animal studies showed that Andrographis paniculata extracts and isolated bioactive compounds have strong anti-inflammatory and antioxidant effects on cardiovascular diseases. These effects lead to lowering the risk of coronary artery disease and myocardial infarction, easing the effects of bad cardiac remodeling, stopping cardiac hypertrophy, and improving diabetic cardiomyopathy. Although SYRCLE's tool detected some bias, the studies were included since they met the inclusion criteria and had no conflicts of interest. Conclusions: Andrographis paniculata may have the potential to be used as a supplementary therapy for cardiovascular diseases, but more animal studies and clinical trials should be done to establish these findings. © 2024 Journal of Pharmacy & Pharmacognosy Research.
Andrographis paniculata; animal models; cardiovascular diseases; herbal medicine; inflammation; oxidative stress
Andrographis paniculata extract; C reactive protein; endothelin 1; lipopolysaccharide; thromboxane A2; Andrographis paniculata; animal experiment; animal model; animal tissue; antiinflammatory activity; cardiovascular disease; cardiovascular effect; cholesterol synthesis; comparative study; computer model; data analysis; enzyme activity; epididymis fat; fatty acid oxidation; heart left ventricle ejection fraction; heart protection; herbal medicine; in vitro study; in vivo study; information processing; insulin signaling; left anterior descending coronary artery; lipid diet; lipid fingerprinting; meta analysis; molecular interaction; mouse; nonhuman; outcome assessment; oxidative stress; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; Review; systematic review
National Key Research and Development Program of China, NKRDPC; Ministry of Science and Technology, China Medical University; Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES; Xinjiang Science and Technology Supported; Hebei University of Chinese Medicine, HUCM; China Medical University, CMU; Asian University; Ministry of Higher Education, Malaysia, MOHE; National Natural Science Foundation of China, NSFC; Uni
Funding text 1: National Key R&D Program of China, Hubei University of Chinese Medicine “Young Crops Program” Project funded this research; Funding text 2: The National Natural Science Foundation of China and Xinjiang Science and Technology Supported with grants Dr. Chen received grants from Ministry of Science and Technology, China Medical University, and Asian University, Taiwan; Funding text 3:
Academic Association of Pharmaceutical Sciences from Antofagasta (ASOCIFA)
07194250
Review
Q2
312
14790